Head-to-head evidence
CS1001 Monoclonal Antibody vs Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-L1 · full Non-Small Cell Lung Cancer pipeline
CS1001 Monoclonal Antibody
Developed by CStone Pharmaceuticals
NCT03728556 · Phase 3 · completed
In this randomized, quadruple-blind, placebo-controlled Phase 3 trial, 381 patients with stage III lung cancer who had completed chemoradiotherapy were randomized to sugemalimab or placebo. Sugemalimab significantly reduced the risk of progression or death compared with placebo (median progression-free survival 10.5 vs 6.2 months).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
Marketed by Roche
NCT03735121 · Phase 3 · completed
This was a randomized, open-label, active-controlled phase 3 study comparing subcutaneous atezolizumab with the established IV formulation in previously treated NSCLC. The primary endpoints were pharmacokinetic measures (serum trough concentration and AUC) rather than clinical outcomes, and the non-inferiority comparisons were met for both. Because the study was open-label and the primary endpoints were surrogate PK measures, the evidence is limited despite the randomized design and adequate sample size.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CS1001 Monoclonal Antibody's landscape · Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)'s landscape